BRIEF-Sierra Metals Board of Directors Rejects Alpayana's Hostile Bid-March 2024-www.financetom.com

BRIEF-Sierra Metals Board of Directors Rejects Alpayana's Hostile Bid

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Sierra Metals Board of Directors Rejects Alpayana's Hostile Bid

Jan 14, 2025 5:24 AM

Jan 14 (Reuters) - Sierra Metals Inc ( SMTSF ):

* SIERRA METALS BOARD OF DIRECTORS REJECTS ALPAYANA'S

HOSTILE BID;

HOSTILE BID'S INADEQUATE OFFER PRICE FAILS TO RECOGNIZE SIERRA

METALS' VALUE AND GROWTH POTENTIAL

* SIERRA METALS INC ( SMTSF ): INTRODUCED PROJECTION OF ABOUT $130

MILLION

OF EBITDA IN 2025

Source text:

Further company coverage:

Previous page： Market Chatter: Ford to Scale Back Diversity, Equity, Inclusion Policies Next page： GSK Says Nucala Approved in Japan to Treat Chronic Rhinosinusitis With Nasal Polyps

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Ford to Scale Back Diversity, Equity, Inclusion Policies

Aug 28, 2024

12:02 PM EDT, 08/28/2024 (MT Newswires) -- Ford Motor ( F ) will change its diversity, equity and inclusion policies and end participation in a ranking by an LGBTQ advocacy group, Bloomberg reported Wednesday, citing an internal e-mail by Chief Executive Jim Farley. We are mindful that our employees and customers hold a wide range of beliefs, Farley said in...

GSK Says Nucala Approved in Japan to Treat Chronic Rhinosinusitis With Nasal Polyps

Aug 28, 2024

07:25 AM EDT, 08/28/2024 (MT Newswires) -- GSK (GSK) said Wednesday that Japan's Ministry of Health, Labor and Welfare had approved Nucala, or mepolizumab, to treat chronic rhinosinusitis with nasal polyps in adults. The approval is based on phase 3 trial data and supported by the results of a global study, GSK said. Mepolizumab is also approved in Japan for...

Infosys Joins Stanford HAI Corporate Affiliate Program to Speed Up AI Research Initiatives

Aug 28, 2024

07:22 AM EDT, 08/28/2024 (MT Newswires) -- Infosys ( INFY ) said Wednesday that it has joined the Stanford University Institute for Human-Centered Artificial Intelligence, or Stanford HAI, corporate affiliate program. The company said the partnership aims to speed up artificial intelligence initiatives. Infosys ( INFY ) said it will discuss themes such as responsible AI, the use of AI...

Revive Therapeutics Updates on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Aug 28, 2024

07:27 AM EDT, 08/28/2024 (MT Newswires) -- Revive Therapeutics ( RVVTF ) on Wednesday said a research study evaluating Bucillamine as a potential treatment for nerve agent exposure, is expected to be completed in October. The study is being conducted in partnership with an agency of the Canadian Department of National Defence. The results from the study, if promising, will...